Headache and GLP-1 receptor agonists: when medications are therapeutic and when they contribute to the symptom
Open Access
- 1 July 2025
- journal article
- review article
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (10) , 001-007
Abstract
Obesity is a complex metabolic disorder with significant implications for both individual and public health. It has been strongly linked to chronic headache conditions, including migraines and idiopathic intracranial hypertension (IIH). Individuals with obesity who suffer from migraine are at increased risk of chronification, while weight reduction has been associated with improvement in IIH-related headaches, likely due to a decrease in cerebrospinal fluid pressure. These observations underscore the importance of weight management strategies as a therapeutic consideration in patients with obesity and headache disorders. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are pharmacological agents that mimic the hormone's endogenous activity. Analysis of selected studies highlights that these agents have emerged as a promising therapeutic option. The aim of this narrative review is to examine the role of GLP-1 RAs in the management of headaches, particularly in the context of IIH, migraine, and the gut–brain axis. Additionally, this review addresses the challenges associated with the use of this pharmaceutical class, including the potential for headaches as adverse effect, and identifies existing knowledge gaps that may guide future research.Keywords
This publication has 38 references indexed in Scilit:
- Pharmacological management of migraine: current strategies and future directionsExpert Opinion on Pharmacotherapy, 2024
- Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013–2020International Journal of Clinical Pharmacy, 2021
- Chronic inflammation in the etiology of disease across the life spanNature Medicine, 2019
- Inflammation, But Not Telomere Length, Predicts Successful Ageing at Extreme Old Age: A Longitudinal Study of Semi-supercentenariansEBioMedicine, 2015
- GLP‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyondObesity, 2015
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trialThe Lancet, 2014
- Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trialThe Lancet Diabetes & Endocrinology, 2014
- Idiopathic Intracranial Hypertension Is Associated with Lower Body AdiposityOphthalmology, 2010
- Idiopathic intracranial hypertension: Can studies of obesity provide the key to understanding pathogenesis?British Journal Of Neurosurgery, 2008
- Serum leptin, food intake and preferences for sugar and fat in obese womenInternational Journal of Obesity, 1998